Chardan Capital Cuts Century Therapeutics (NASDAQ:IPSC) Price Target to $7.00

Century Therapeutics (NASDAQ:IPSC) had its target price lowered by Chardan Capital from $11.00 to $7.00 in a research report released on Monday morning,Benzinga reports. The brokerage currently has a buy rating on the stock.

IPSC has been the topic of a number of other research reports. HC Wainwright restated a “buy” rating and issued a $5.00 target price on shares of Century Therapeutics in a research note on Wednesday, January 22nd. Guggenheim lowered their price target on Century Therapeutics from $12.00 to $5.00 and set a “buy” rating for the company in a research note on Friday, March 21st. Finally, Piper Sandler cut their price objective on shares of Century Therapeutics from $4.00 to $2.00 and set an “overweight” rating on the stock in a research report on Thursday, March 20th. Five equities research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, Century Therapeutics currently has a consensus rating of “Buy” and a consensus target price of $5.00.

Century Therapeutics Price Performance

Shares of IPSC opened at $0.56 on Monday. The business’s 50-day moving average is $0.72 and its 200-day moving average is $1.14. The company has a market capitalization of $47.84 million, a price-to-earnings ratio of -0.30 and a beta of 1.75. Century Therapeutics has a fifty-two week low of $0.52 and a fifty-two week high of $4.43.

Century Therapeutics (NASDAQ:IPSC) last released its quarterly earnings data on Wednesday, March 19th. The company reported ($0.43) earnings per share for the quarter, beating the consensus estimate of ($0.45) by $0.02. Century Therapeutics had a negative net margin of 4,837.73% and a negative return on equity of 61.66%. The firm had revenue of $4.18 million for the quarter, compared to analyst estimates of $0.67 million. Equities research analysts expect that Century Therapeutics will post -1.61 earnings per share for the current fiscal year.

Institutional Trading of Century Therapeutics

Several large investors have recently made changes to their positions in IPSC. Marshall Wace LLP acquired a new position in Century Therapeutics during the fourth quarter valued at approximately $36,000. Jane Street Group LLC boosted its holdings in shares of Century Therapeutics by 166.2% during the 4th quarter. Jane Street Group LLC now owns 48,036 shares of the company’s stock worth $49,000 after buying an additional 29,992 shares during the period. Two Sigma Advisers LP acquired a new position in Century Therapeutics during the 4th quarter worth $52,000. Sei Investments Co. acquired a new position in Century Therapeutics during the 4th quarter worth $53,000. Finally, Two Sigma Investments LP bought a new stake in Century Therapeutics during the fourth quarter valued at about $67,000. Institutional investors own 50.20% of the company’s stock.

Century Therapeutics Company Profile

Century Therapeutics, Inc, a biotechnology company, engages in the development of genetically engineered allogeneic cell therapies for the treatment of solid tumor and hematological malignancies. Its lead product candidate is CNTY-101, an allogeneic, induced pluripotent stem cells (iPSCs)-derived chimeric antigen receptors (CAR)-iNK cell therapy, under Phase 1 trials targeting CD19 for relapsed, refractory B-cell lymphoma.